Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease

Osamu Kano,1 Yoshihisa Urita,2 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Takehisa Hirayama,1 Ken Miura,1 Yuichi Ishikawa,1 Tetsuhito Kiyozuka,3 Jo Aoyagi,3 Yasuo Iwasaki11Department of Neurology, 2Department of General Medicine and Emergency Care, Toho University Omori Medical C...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kano O, Urita Y, Ito H, Takazawa T, Kawase Y, Murata K, Hirayama T, Miura K, Ishikawa Y, Kiyozuka T, Aoyagi J, Iwasaki Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/cf7d77145c7c41af97e4e8d74be34fd2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:cf7d77145c7c41af97e4e8d74be34fd2
record_format dspace
spelling oai:doaj.org-article:cf7d77145c7c41af97e4e8d74be34fd22021-12-02T02:57:36ZDomperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease1176-63281178-2021https://doaj.org/article/cf7d77145c7c41af97e4e8d74be34fd22013-09-01T00:00:00Zhttp://www.dovepress.com/domperidone-effective-in-preventing-rivastigmine-related-gastrointesti-a14396https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Osamu Kano,1 Yoshihisa Urita,2 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Takehisa Hirayama,1 Ken Miura,1 Yuichi Ishikawa,1 Tetsuhito Kiyozuka,3 Jo Aoyagi,3 Yasuo Iwasaki11Department of Neurology, 2Department of General Medicine and Emergency Care, Toho University Omori Medical Center, Tokyo, Japan; 3Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Mishuku Hospital, Tokyo, JapanObjective: While acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, are beneficial in treating behavioral symptoms of patients with Alzheimer's disease (AD), their dose-limiting effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. We aimed to predict the occurrence of these gastrointestinal disturbances with rivastigmine therapy for optimal drug choice and improved compliance.Materials and methods: Thirty patients with mild-to-moderate AD (scores 10–22 on the Mini-Mental State Examination) were administered a rivastigmine 18 mg patch with domperidone 30 mg (RWD) and without domperidone (RWOD; n = 15 each) for 20 weeks. Gastrointestinal disturbances were evaluated using a frequency scale for symptoms of gastroesophageal reflux disease (FSSG), Bristol stool form scale, laboratory data (hemoglobin, albumin, total cholesterol), body weight, and amount of food intake.Results: After 12 weeks, FSSG scores were higher in the RWOD group compared to baseline scores; however, no significant differences were noted between the RWD and RWOD groups. We then subdivided each group based on high and low baseline scores; the RWOD high-score (≥4) subgroup showed increased FSSG after 12 weeks compared with the baseline score. In both RWD and RWOD groups, the low-score (≤3) subgroups showed no changes during the dose-escalation phase.Conclusion: For AD patients with higher FSSG scores at baseline, domperidone was effective in preventing rivastigmine-related gastrointestinal disturbances.Keywords: Alzheimer's disease, acetylcholinesterase inhibitors, domperidone, gastroesophageal reflux disease, gastrointestinal disturbance, rivastigmineKano OUrita YIto HTakazawa TKawase YMurata KHirayama TMiura KIshikawa YKiyozuka TAoyagi JIwasaki YDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1411-1415 (2013)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Kano O
Urita Y
Ito H
Takazawa T
Kawase Y
Murata K
Hirayama T
Miura K
Ishikawa Y
Kiyozuka T
Aoyagi J
Iwasaki Y
Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
description Osamu Kano,1 Yoshihisa Urita,2 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Takehisa Hirayama,1 Ken Miura,1 Yuichi Ishikawa,1 Tetsuhito Kiyozuka,3 Jo Aoyagi,3 Yasuo Iwasaki11Department of Neurology, 2Department of General Medicine and Emergency Care, Toho University Omori Medical Center, Tokyo, Japan; 3Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations, Mishuku Hospital, Tokyo, JapanObjective: While acetylcholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, are beneficial in treating behavioral symptoms of patients with Alzheimer's disease (AD), their dose-limiting effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. We aimed to predict the occurrence of these gastrointestinal disturbances with rivastigmine therapy for optimal drug choice and improved compliance.Materials and methods: Thirty patients with mild-to-moderate AD (scores 10–22 on the Mini-Mental State Examination) were administered a rivastigmine 18 mg patch with domperidone 30 mg (RWD) and without domperidone (RWOD; n = 15 each) for 20 weeks. Gastrointestinal disturbances were evaluated using a frequency scale for symptoms of gastroesophageal reflux disease (FSSG), Bristol stool form scale, laboratory data (hemoglobin, albumin, total cholesterol), body weight, and amount of food intake.Results: After 12 weeks, FSSG scores were higher in the RWOD group compared to baseline scores; however, no significant differences were noted between the RWD and RWOD groups. We then subdivided each group based on high and low baseline scores; the RWOD high-score (≥4) subgroup showed increased FSSG after 12 weeks compared with the baseline score. In both RWD and RWOD groups, the low-score (≤3) subgroups showed no changes during the dose-escalation phase.Conclusion: For AD patients with higher FSSG scores at baseline, domperidone was effective in preventing rivastigmine-related gastrointestinal disturbances.Keywords: Alzheimer's disease, acetylcholinesterase inhibitors, domperidone, gastroesophageal reflux disease, gastrointestinal disturbance, rivastigmine
format article
author Kano O
Urita Y
Ito H
Takazawa T
Kawase Y
Murata K
Hirayama T
Miura K
Ishikawa Y
Kiyozuka T
Aoyagi J
Iwasaki Y
author_facet Kano O
Urita Y
Ito H
Takazawa T
Kawase Y
Murata K
Hirayama T
Miura K
Ishikawa Y
Kiyozuka T
Aoyagi J
Iwasaki Y
author_sort Kano O
title Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
title_short Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
title_full Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
title_fullStr Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
title_full_unstemmed Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease
title_sort domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with alzheimer's disease
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/cf7d77145c7c41af97e4e8d74be34fd2
work_keys_str_mv AT kanoo domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT uritay domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT itoh domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT takazawat domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT kawasey domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT muratak domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT hirayamat domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT miurak domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT ishikaway domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT kiyozukat domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT aoyagij domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
AT iwasakiy domperidoneeffectiveinpreventingrivastigminerelatedgastrointestinaldisturbancesinpatientswithalzheimer39sdisease
_version_ 1718402069623209984

Ejemplares similares